linjc16/ctgov huggingface dataset:
The Diagnosis of Occult Deep Vein Thrombosis of the Lower Extremities in Patients Presenting With Hypoxia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to prove that bedside Ultrasound Compression is a useful screening tool for the diagnosis of occult deep vein thrombosis in patients presenting to the emergency room with hypoxia.

Detailed Description
-----------------
It is known that 30% of deep vein thrombosis of the extremities is belived to be the precedend of pulmonary emboli; an often fatal disease. It is known that DVT (deep vein thrombosis is often occult. It is also known that pulmonary embolism is often difficult to diagnose and is often missed especialy in patients with chronic illnesses such as COPD and CHF. Venous compression ultrsound is an exam that can be preformed bedside. It is preformed by placing a vascular ultrasound transducer on the femoral vein and popliteal and checking its compressibility. If DVT is present in the femoral or popliteal veins the veins will be noncompressible. It has been shown that US compression for DVT can be preformed by physicians in the ER with accuracy and speed. Presently US compression is not a tool used for detection of occult DVT in the ER. I wish to explore the usefullness of compression US of the lower extremities as a screening tool for DVT In the hypoxic patient.

Official Title
-----------------
The Diagnosis of Occult Deep Vein Thrombosis of the Lower Extremities in Patients Presenting With Hypoxia

Conditions
-----------------
Hypoxia

Intervention / Treatment
-----------------
* Device: Ultrasound compression of femoral and popliteal veins


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients presenting to the Emergency room 18 years or older, saturation 94% and under on room air. Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ultrasond compression of deep veins<br> | Device: Ultrasound compression of femoral and popliteal veins<br>* Bedside ultrasound compression of femoral and popliteal veins.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
DVT Ultrasound compression Hypoxia Pulmonary Emboli, Occult DVT in hypoxic patients
A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer

Study Overview
=================
Brief Summary
-----------------
Comparing the effect of switching from Lupron and Zoladex to Eligard. PSA and Testosterone levels are measured at set intervals to determine if Eligard is equal or better then Lupron or Zoladex in advanced Prostate Cancer patients.

Official Title
-----------------
A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer

Conditions
-----------------
Cancer of Prostate

Intervention / Treatment
-----------------
* Drug: leuprolide acetate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with Advanced Ca, on stable dose of Lupron or Zoladex - Exclusion Criteria: Previous exposure to Eligard.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: leuprolide acetate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Long Term Follow-Up Results Of The Direct Nipple Ureteroneocystostomy Technique

Study Overview
=================
Brief Summary
-----------------
To evaluate the long term follow-up results of the direct nipple ureteroneocystostomy technique.

Official Title
-----------------
The Long Term Follow-Up Results Of The Direct Nipple Ureteroneocystostomy Technique: A Prospective Study

Conditions
-----------------
Vesicoureteral Reflux, Nipple Ureteroneocystostomy

Intervention / Treatment
-----------------
* Procedure: The Direct Nipple Ureteroneocystostomy Technique


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Megaureter. Ligated Ureter during surgery. Exclusion Criteria: Neurogenic bladder Surgical wound infection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Direct Nipple Ureteroneocystostomy<br> | Procedure: The Direct Nipple Ureteroneocystostomy Technique<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inter-IVU image differences and DMSA uptakes | In cases attending regular follow-ups, preoperative and postoperative 1st year DMSA results and amount of pelvicaliceal dilatation in the IVU of the unit that underwent surgery were compared statistically (by counting the dots falling on the pelvis and calices using stereologic methods which use transparent acetates with 3-mm inter-grid distances. Inter-IVU image differences between IVUs taken at different centers were resolved by using the value found by counting the dots falling on the 4th lumbar vertebra in both films and proportioning the results with each other as the multiplier. Measurable values were expressed as means + standard deviation. | 3 month after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nipple, Technique, Ureter, Vesicoureteral Reflux
Addressing Dementia Via Agitation-Centered Evaluation

Study Overview
=================
Brief Summary
-----------------
This is a multi-center, randomized, double-blind, placebo-controlled study, to assess the efficacy and safety of AXS-05 in the treatment of agitation in patients with Alzheimer's disease.

Official Title
-----------------
A Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of AXS-05 for the Treatment of Agitation in Subjects With Dementia of the Alzheimer's Type

Conditions
-----------------
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor

Intervention / Treatment
-----------------
* Drug: AXS-05
* Drug: Bupropion
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Key Inclusion Criteria: Diagnosis of probable Alzheimer's disease (AD) based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria. Diagnosis of clinically signification agitation resulting from probable AD according to the International Psychogeriatric Association (IPA) provisional definition of agitation. Exclusion Criteria: Patient has dementia predominantly of non-Alzheimer's type. Unable to comply with study procedures. Medically inappropriate for study participation in the opinion of the investigator.

Ages Eligible for Study
-----------------
Minimum Age: 65 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AXS-05<br>AXS-05 tablets taken by mouth for 5 weeks. | Drug: AXS-05<br>* AXS-05<br>|
| Active Comparator: Bupropion<br>Bupropion tablets taken by mouth for 5 weeks. | Drug: Bupropion<br>* Bupropion<br>|
| Placebo Comparator: Placebo<br>Placebo tablets taken by mouth for 5 weeks. | Drug: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in CMAI Total Score | The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item caregiver-rated questionnaire that assesses the frequency of agitation-related and disruptive behaviors in subjects with dementia. The scale contains 29 behaviors or items organized into four subscales: physically aggressive, physically non-aggressive, verbally aggressive, and verbally non-aggressive. The CMAI is administered by interviewing the caregiver and asking him or her to rate the frequency with which the subject manifests each behavior using a seven-point scale: 1=never (better outcome), 7=several times an hour (worse outcome). The CMAI total score is the sum of the scores for all of the items in the CMAI. CMAI total scores range from a minimum of 29 (better outcome) to a maximum of 203 (worse outcome). | 5 weeks |
Effect of Combined Aerobic and Resisted Exercise in Breast Cancer Survivors

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the effects of a combined aerobic and resistance exercise program in breast cancer survivors.

Detailed Description
-----------------
Cancer and cancer treatment side effects are associated with fatigue, pain, decreased cardiovascular fitness and muscle strength, and overall quality of life. Furthermore, cancer survivors are at increased risk for cancer recurrence and for secondary effect such as cardiovascular disease, diabetes, obesity, osteoporosis, and functional decline. Increase physical activity or exercise is proposed to overcome the negative psychological and physiological effects. Preliminary research evidence shows that exercise in cancer survivors improves quality of life, cardiorespiratory fitness, physical functioning, and decrease of fatigue. However, the best exercise mode and intensity has not been well established. Little is known regarding the long term effect. No study investigated impact of exercise for breast cancer survivors on upper extremity function, and correlation between fitness, upper extremity function and quality of life.

Official Title
-----------------
Effect of Combined Aerobic and Resisted Exercise in Breast Cancer Survivors: Upper Extremity Function, Quality of Life and Fitness Outcomes

Conditions
-----------------
Breast Cancer, Exercise, Physical Function

Intervention / Treatment
-----------------
* Other: exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: stage 0 to II breast cancer diagnosed within 5 years complete adjuvant therapy > 2 months, except hormone therapy > 18 years Exclusion Criteria: disease in progress, recurrent, or metastasis medical or musculoskeletal condition which resistance exercise is contraindicated medication which may alter exercise response

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: exercise<br>supervised combined aerobic and resistance training for 12 weeks | Other: exercise<br>* supervised combined aerobic and progressive resistance training for 12 weeks<br>|
| No Intervention: control<br>waist list control with usual care | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| muscle fitness, quality of life, upper extremity function |  | baseline, 12 weeks post exercise training and follow up 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
breast cancer, exercise, upper extremity function, quality of life
Accuracy of Pulse Oximeters With Profound Hypoxia

Study Overview
=================
Brief Summary
-----------------
This project aims to test the accuracy of pulse oximeters during mild, moderate, and severe hypoxia, i.e., a range of arterial HbO2 saturation from 100 down to 70%. A typical study will include at least ten subjects (at least 200 necessary data points to meet the ISO 80601-2-61:2017).

Detailed Description
-----------------
After local anesthetic injection, a 22-gauge catheter is inserted in one radial artery. Pulse oximeters are attached to fingers, ears, or flat body surfaces. Subjects are in a comfortable semi-recumbent position. Subjects then breathe air mixtures containing reduced amounts of oxygen to produce the desired level of hypoxemia. Stable, safe, and controlled hypoxia is breath-by-breath by breath respiratory gas analysis and a computer program that permits the inspired gas mixture to be adjusted to achieve a level of lung alveolar gas that will achieve the desired degree of saturation.

Official Title
-----------------
Accuracy of Pulse Oximeters With Profound Hypoxia - Test Protocol

Conditions
-----------------
SpO2

Intervention / Treatment
-----------------
* Procedure: A-line


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The subject is male or female, aged ≥18 and <50. The subject is in good general health with no evidence of any medical problems. The subject is fluent in both written and spoken English. The subject has provided informed consent and is willing to comply with the study procedures. Exclusion Criteria: The subject is obese (BMI>30). The subject has a known history of heart disease, lung disease, kidney or liver disease. Diagnosis of asthma, sleep apnea, or use of CPAP. Subject has diabetes. Subject has a clotting disorder.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Single<br>Subjects undergo an interventional procedure and non-invasive measurements of SpO2. | Procedure: A-line<br>* Subjects breathe air mixtures containing reduced amounts of oxygen to produce the desired level of hypoxemia.<br>* Other names: Hypoxemia;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of pulse oximeter with profound hypoxia | Perform accurate measurement of a range of arterial HbO2 saturation from 100 to down to 70% during mild, moderate, and severe hypoxia. | 2 days |
Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to investigate the efficacy, safety, tolerability and pharmacokinetics of multiple oral administration of MT-3995 in patients with NASH.

Official Title
-----------------
An Exploratory Study of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH) (Placebo-Controlled Double-Blind Study)

Conditions
-----------------
NASH

Intervention / Treatment
-----------------
* Drug: MT-3995
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects diagnosed with NASH before randomization Subjects who conducts diet or exercise therapy at the beginning of run in period. Subjects who has given full and adequate information of the protocol and with written informed consent Exclusion Criteria: Subjects with hepatic failure or previously diagnosed with hepatic cirrhosis Subjects with alcohol dependence or previously diagnosed with alcohol dependence Subjects with other chronic liver disease (e.g., primary sclerosing cholangitis, alcoholic liver damage, hemochromatosis, Wilson's disease) Presence, history, or family history of long QT syndrome or Torsades de Pointes Subjects with heart failure (New York Heart Association Class III-IV)

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MT-3995<br> | Drug: MT-3995<br> <br> |
| Placebo Comparator: Placebo<br> | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent change from baseline in ALT |  | 24 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in ALT |  | 24 weeks | 
| Adverse events |  | From baseline to 72 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NASH
Technique for Localization of Pulmonary Nodules Using Spy Thoracoscope System

Study Overview
=================
Brief Summary
-----------------
This study will determine the feasibility of the novel Indocyanine Green (ICG) fluorescence localization technique with a Laser fluorescence thoracoscope system. The primary objective of this study is to prove the validity and safety of our novel fluorescent localization method with utilized ICG and novel near infra-red fluorescence videoscope system.

Official Title
-----------------
Feasibility of a Novel Minimally Invasive Technique for Localization of Pulmonary Nodules Using the Spy Thoracoscope System

Conditions
-----------------
Lung Cancer

Intervention / Treatment
-----------------
* Other: ICG Localization with Spy thoracoscope localization


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any patient scheduled for a VATS wedge lung resection using CT guided micro-coil lung implantation for the localization of the lung lesion. Exclusion Criteria: Any patients with an allergy to iodine, shellfish, or cough mixture, betadine or other iodine contrast agents. Pregnant or potentially pregnant women.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: VATS wedge lung resection<br> | Other: ICG Localization with Spy thoracoscope localization<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Compare incidence of Adverse Events (AE) occurrence due to ICG injection with micro-coil placement versus overall AE occurrence for micro-coil placement alone. |  | Within 4 hours of ICG injection |
A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the benefit of Cellworks Singula™ and Ventura™ reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indications. Cellworks reports aim to provide NGS-based therapy recommendations to aid the decision-making of patients, physicians, and molecular tumor boards.

Official Title
-----------------
A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients

Conditions
-----------------
Pan-cancer

Intervention / Treatment
-----------------
* Other: Cellworks Singula and Ventura reports


Participation Criteria
=================
Eligibility Criteria
-----------------
Have any stage of cancer for the indications listed at: https://cellworks.life/mycare101 Patients are eligible at any stage of disease. Expected to be alive 6 months or more Requirements for NGS testing (e.g., panel or whole-exome sequencing): NGS testing has been ordered from or performed by one or more vendors specified at: https://cellworks.life/mycare101 . NGS reports must be ordered or performed within the last 90 days. Cellworks will accept all NGS input formats available, including PDF, VCF, BAM, and FastQ. Requirements for additional laboratory testing If Hematological Indication, Cytogenetics in the form of FISH, Karyotyping, IHC, and/or aCGH has been ordered If Acute Myeloid Leukemia (AML), FLT3-itd testing has been ordered If Indication is a form of Brain Cancer (e.g., glioblastoma), Cytogenetics in the form of FISH, Karyotyping, IHC, and/or aCGH has been ordered and MGMT Methylation test has been ordered
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Cellworks Singula and Ventura reports|Personalized drug match reports based on patients' genomic aberration.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physician satisfaction on Cellworks reports | A questionnaire will be administered following receipt of the Cellworks report. Survey questions will be performed using a 6-point forced response Likert scale. Simple descriptive statistics, including medians, mode and range of the resulting Likert scores, will be reported but can lead to incorrect effect size estimates, inflated error rates, and other issues (Bürkner & Vuorre, 2019). For hypothesis testing purposes, the proportion of physicians and MTB's with a favorable response (i.e., Likert score of 4 or above) will be estimated along with exact (Clopper-Pearson) 95% two-sided confidence intervals. | 2022.1 - 2023.1 |